Cargando…

Aprepitant inhibits the progression of esophageal squamous cancer by blocking the truncated neurokinin‑1 receptor

Increasing evidence showed that the substance P (SP)/neurokinin-1 receptor (NK1R) complex is involved in the development of several cancers. However, little is known about the mechanisms by which SP/NK1R complex plays a role in esophageal squamous cell carcinoma (ESCC) progression. RT-qPCR, CCK-8, T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Yang, Sang, Meixiang, Liu, Fei, Gu, Lina, Li, Juan, Wu, Yunyan, Shan, Baoen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236268/ https://www.ncbi.nlm.nih.gov/pubmed/37203393 http://dx.doi.org/10.3892/or.2023.8568

Ejemplares similares

Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy
por: Ständer, Sonja, et al.
Publicado: (2010)

The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
por: Muñoz, Miguel, et al.
Publicado: (2020)

circCYP24A1 facilitates esophageal squamous cell carcinoma progression through binding PKM2 to regulate NF-κB-induced CCL5 secretion
por: Gu, Lina, et al.
Publicado: (2022)

Correction: circCYP24A1 facilitates esophageal squamous cell carcinoma progression through binding PKM2 to regulate NF-κB-induced CCL5 secretion
por: Gu, Lina, et al.
Publicado: (2023)

Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting
por: Lim, Chae Seong, et al.
Publicado: (2013)

GPCR large-amplitude dynamics by (19)F-NMR of aprepitant bound to the neurokinin 1 receptor
por: Pan, Benxun, et al.
Publicado: (2022)

The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant
por: Coveñas, Rafael, et al.
Publicado: (2023)

MAGE‐A gene expression in peripheral blood serves as a poor prognostic marker for patients with lung cancer
por: Gu, Lina, et al.
Publicado: (2018)

The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia
por: Muñoz, Miguel, et al.
Publicado: (2020)

Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors
por: Halik, Paweł K., et al.
Publicado: (2020)

The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis
por: Alsaeed, Mohammed Ali, et al.
Publicado: (2022)

Neurokinin-1 Receptor Inhibition and Cough
por: Turner, Richard D., et al.
Publicado: (2021)

MicroRNA-485-5p suppresses the progression of esophageal squamous cell carcinoma by targeting flotillin-1 and inhibits the epithelial-mesenchymal transition
por: Zhao, Riyang, et al.
Publicado: (2021)

5-aza-2’-deoxycytidine (DAC) treatment induces the MAGE-A10 expression and improves the cytotoxicity of MAGE-A10-specific CTLs in lung cancer cells
por: Li, Zhenhua, et al.
Publicado: (2020)

Investigation of the Role of Neurokinin-1 Receptor Inhibition Using Aprepitant in the Apoptotic Cell Death through PI3K/Akt/NF-κB Signal Transduction Pathways in Colon Cancer Cells
por: Ghahremanloo, Atefeh, et al.
Publicado: (2021)

The circRNA circADAMTS6 promotes progression of ESCC and correlates with prognosis
por: Bu, Jing, et al.
Publicado: (2022)

Structural insights into the activation of neurokinin 2 receptor by neurokinin A
por: Sun, Wenjing, et al.
Publicado: (2022)

Circular RNA circ‐TNRC6B inhibits the proliferation and invasion of esophageal squamous cell carcinoma cells by regulating the miR‐452‐5p/DAG1 axis
por: Xu, Ruiyu, et al.
Publicado: (2023)

METTL3 Facilitates Tumor Progression by COL12A1/MAPK Signaling Pathway in Esophageal Squamous Cell Carcinoma
por: Li, Jiali, et al.
Publicado: (2022)

A Randomized, Placebo Controlled, Double Masked Phase IB Study Evaluating the Safety and Antiviral Activity of Aprepitant, a Neurokinin-1 Receptor Antagonist in HIV-1 Infected Adults
por: Tebas, Pablo, et al.
Publicado: (2011)

Activation of circ_0072088/miR‐1261/PIK3CA pathway accelerates lung adenocarcinoma progression
por: Cao, Feng, et al.
Publicado: (2022)

Identification of potential circular RNA biomarkers in lung adenocarcinoma: A bioinformatics analysis and retrospective clinical study
por: Zhu, Yonggang, et al.
Publicado: (2022)

Expression of Neurokinin B Receptor in the Gingival Squamous Cell Carcinoma Bone Microenvironment
por: Yoshida, Shoko, et al.
Publicado: (2021)

Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation
por: Cao, Xueyan, et al.
Publicado: (2023)

ESM1 Is a Promising Therapeutic Target and Prognostic Indicator for Esophageal Carcinogenesis/Esophageal Squamous Cell Carcinoma
por: Li, Juan, et al.
Publicado: (2022)

Effect of Monotherapy and Combination Therapy of Pantoprazole and Aprepitant in Gastric Esophageal Reflux Disease in Albino Rats
por: Shukla, Kamleshwar, et al.
Publicado: (2014)

Neurokinin-2 receptor negatively modulates substance P responses by forming complex with Neurokinin-1 receptor
por: Nguyen, Lan Phuong, et al.
Publicado: (2023)

Aprepitant Inhibits JNK and p38/MAPK to Attenuate Inflammation and Suppresses Inflammatory Pain
por: Yang, Yang, et al.
Publicado: (2022)

The interaction of ifosfamide and aprepitant in gynecologic malignancies()
por: Shindorf, Mackenzie L., et al.
Publicado: (2013)

Aprepitant for the Treatment of Chronic Refractory Pruritus
por: He, Alice, et al.
Publicado: (2017)

Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects
por: Yang, Meng-Jie, et al.
Publicado: (2020)

Neurokinin 1 Receptor Antagonists for Pruritus
por: Alam, Majid, et al.
Publicado: (2021)

Proteomic and Phosphoproteomic Analysis Reveals that Neurokinin-1 Receptor (NK1R) Blockade with Aprepitant in Human Keratinocytes Activates a Distinct Subdomain of EGFR Signaling: Implications for the Anti-Pruritic Activity of NK1R Antagonists
por: Kwatra, Shawn G., et al.
Publicado: (2019)

Treatment for Refractory Pruritus Using Oral Aprepitant
por: Huh, Joon Won, et al.
Publicado: (2016)

Aprepitant for the management of nausea with inpatient IV dihydroergotamine
por: Chou, Denise E., et al.
Publicado: (2016)

Emerging Role of Aprepitant in Cannabis Hyperemesis Syndrome
por: Parvataneni, Swetha, et al.
Publicado: (2019)

Neurokinin-1 Receptor Activation in Globus Pallidus
por: Chen, Lei, et al.
Publicado: (2009)

The pharmacology of neurokinin receptors in addiction: prospects for therapy
por: Sandweiss, Alexander J, et al.
Publicado: (2015)

Neurokinin-1 Receptor Antagonists against Hepatoblastoma
por: Muñoz, Miguel, et al.
Publicado: (2019)

Neurokinin receptors and their implications in various autoimmune diseases
por: Mishra, Amrita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0b9baqi3944ntqk7pqifo0a4j5